Idorsia Valuation

Is IDIA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IDIA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IDIA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IDIA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IDIA?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for IDIA. This is calculated by dividing IDIA's market cap by their current preferred multiple.
What is IDIA's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CHF 315.32m

IDIA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	10.4x
Enterprise Value/EBITDA	-3.9x
PEG Ratio	-0.5x

Price to Earnings Ratio vs Peers

How does IDIA's PE Ratio compare to its peers?

The above table shows the PE ratio for IDIA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	17.1x
SANN Santhera Pharmaceuticals Holding	2x	32.5%	CHF 108.1m
XLS Xlife Sciences	10.3x	n/a	CHF 152.7m
VYGR Voyager Therapeutics	37x	-24.1%	US$334.3m
COPN Cosmo Pharmaceuticals	19.2x	-3.3%	CHF 1.2b
IDIA Idorsia	11x	-20.4%	CHF 315.3m

Price-To-Earnings vs Peers: IDIA is good value based on its Price-To-Earnings Ratio (11x) compared to the peer average (17.1x).

Price to Earnings Ratio vs Industry

How does IDIA's PE Ratio compare vs other companies in the European Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.8%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: IDIA is good value based on its Price-To-Earnings Ratio (11x) compared to the European Biotechs industry average (26.4x).

Price to Earnings Ratio vs Fair Ratio

What is IDIA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IDIA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	11x
Fair PE Ratio	11.6x

Price-To-Earnings vs Fair Ratio: IDIA is good value based on its Price-To-Earnings Ratio (11x) compared to the estimated Fair Price-To-Earnings Ratio (11.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IDIA forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	CHF 1.75	CHF 1.78 +1.7%	31.9%	CHF 2.60	CHF 1.00	n/a	5
Sep ’25	CHF 2.14	CHF 1.78 -16.9%	31.9%	CHF 2.60	CHF 1.00	n/a	5
Aug ’25	CHF 2.55	CHF 1.76 -31.2%	29.6%	CHF 2.60	CHF 1.00	n/a	6
Jul ’25	CHF 2.10	CHF 1.69 -19.4%	31.1%	CHF 2.60	CHF 1.00	n/a	8
Jun ’25	CHF 2.59	CHF 1.69 -34.8%	31.1%	CHF 2.60	CHF 1.00	n/a	8
May ’25	CHF 1.81	CHF 1.72 -4.8%	32.0%	CHF 2.60	CHF 1.00	n/a	8
Apr ’25	CHF 2.83	CHF 2.10 -25.8%	41.1%	CHF 4.00	CHF 1.00	n/a	8
Mar ’25	CHF 1.99	CHF 2.07 +3.8%	41.7%	CHF 4.00	CHF 1.00	n/a	8
Feb ’25	CHF 1.47	CHF 2.07 +40.9%	41.7%	CHF 4.00	CHF 1.00	n/a	8
Jan ’25	CHF 2.11	CHF 2.07 -2.2%	41.7%	CHF 4.00	CHF 1.00	n/a	8
Dec ’24	CHF 2.18	CHF 2.63 +20.6%	64.5%	CHF 6.50	CHF 1.00	n/a	8
Nov ’24	CHF 1.70	CHF 4.24 +149.0%	79.2%	CHF 12.00	CHF 1.00	n/a	8
Oct ’24	CHF 2.59	CHF 6.38 +146.1%	36.3%	CHF 12.00	CHF 4.00	n/a	8
Sep ’24	CHF 5.24	CHF 6.28 +19.9%	35.1%	CHF 12.00	CHF 4.00	CHF 2.14	9
Aug ’24	CHF 6.90	CHF 5.79 -16.1%	13.1%	CHF 6.50	CHF 4.20	CHF 2.55	7
Jul ’24	CHF 6.45	CHF 10.91 +69.1%	62.8%	CHF 30.00	CHF 6.00	CHF 2.10	10
Jun ’24	CHF 7.99	CHF 13.72 +71.8%	57.0%	CHF 30.00	CHF 7.00	CHF 2.59	9
May ’24	CHF 8.59	CHF 13.46 +56.7%	56.6%	CHF 30.00	CHF 6.00	CHF 1.81	10
Apr ’24	CHF 10.02	CHF 15.23 +52.0%	39.7%	CHF 30.00	CHF 9.00	CHF 2.83	11
Mar ’24	CHF 12.70	CHF 15.23 +20.0%	39.7%	CHF 30.00	CHF 9.00	CHF 1.99	11
Feb ’24	CHF 15.18	CHF 17.43 +14.8%	39.2%	CHF 36.00	CHF 10.00	CHF 1.47	11
Jan ’24	CHF 13.42	CHF 18.17 +35.4%	39.1%	CHF 36.00	CHF 10.00	CHF 2.11	11
Dec ’23	CHF 14.36	CHF 19.65 +36.9%	35.0%	CHF 36.00	CHF 10.00	CHF 2.18	11
Nov ’23	CHF 16.23	CHF 19.71 +21.4%	34.8%	CHF 36.00	CHF 10.00	CHF 1.70	10
Oct ’23	CHF 12.86	CHF 22.91 +78.2%	33.2%	CHF 36.00	CHF 10.00	CHF 2.59	10
Sep ’23	CHF 14.36	CHF 24.92 +73.6%	25.4%	CHF 36.00	CHF 15.00	CHF 5.24	11

Analyst Forecast: Target price is less than 20% higher than the current share price.